Opdivo meets OS endpoint in esophageal cancer trial

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) said anti-PD-1 mAb Opdivo nivolumab met the primary endpoint vs. chemotherapy of improving overall survival in the Phase III

Read the full 243 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE